Custom Antibody Services Market is expected to reach US$ 1,216.35 million by 2031

Monoclonal Segment to Lead Custom Antibody Services Market Based on Product Type During 2023–2031

According to our new research study on “Custom Antibody Services Market Forecast to 2031 – Global Analysis – by Product Type, Service Type, Application, Source, Disease Indication, and End User,” the market was valued at US$ 590.33 million in 2023 and is projected to reach US$ 1,216.35 million by 2031; it is expected to register a CAGR of 9.5% from 2023 to 2031. Major factors driving the market include the rising prevalence of chronic diseases and growing approvals of biosimilars. However, the high costs and complexities associated with antibody production using transgenic animals hinder the market growth.  

Custom antibodies provide long-term protection against toxins, pathogens, allergens, and infections. These antibodies are used to treat specific health issues such as rheumatoid arthritis, heart disease, cancer, and more. Custom antibody services are specialized services provided by companies to develop antibodies tailored to specific needs for research, diagnostic, and therapeutic purposes. These services include the entire process, from antigen design, immunization, and antibody production to purification and validation. Due to the complex nature of antibody development, these services are crucial in supporting academic research, pharmaceutical drug discovery, and the development of diagnostic tools. The increasing demand for personalized medicine, the growing incidence of chronic diseases, and the constant need for new diagnostics and therapeutics are contributing to the growing custom antibody services market size.

Custom Antibody Services Market, by Region, 2023 (%)

Source: The Insight Partners Analysis

Custom Antibody Services Market Analysis Based on Segmental Evaluation:

Based on product type, the custom antibody services market is categorized into monoclonal, polyclonal hybridoma, recombinant antibody, and others. In 2023, the monoclonal segment held a significant custom antibody services market share. Monoclonal antibodies (mAbs) possess strong binding affinity, selectivity, and specificity. mAbs strong position is particularly attributed to the segment's crucial role in various medical purposes, including therapy, research, and diagnosis. Monoclonal antibody's high purity and reproducibility properties are widely utilized in many applications, including medicines, leading to faster results, lower toxicity, and enhanced safety compared to chemotherapy drugs; this improves the well-being and survival rates of patients and reduces adverse side effects with increased effectiveness. Cancer is one of the significant application areas for monoclonal antibodies. mAbs are highly used for their ability to precisely target antigens, particularly in treating cancer, rheumatoid arthritis, autoimmune diseases, and infectious diseases. These are widely accepted biologics and are expected to present a lucrative opportunity to pharmaceutical manufacturers over the forecast period.

Rising awareness among patients and physicians about the applications of mAb therapy is contributing to its growth worldwide. Biotechnology and genetic engineering enhancements have notably improved the production efficiency and effectiveness of monoclonal antibodies. Advancements in technologies such as hybridoma and recombinant DNA have made these antibodies more accessible and cost-effective for a wide range of applications. GenScript has a proven record of successful custom mAb generation and utilizes proprietary techniques to maximize the chances of generating mAbs of high specificity and affinity. The company’s custom mAb services can be adapted to cater to numerous project complexities.

The regulatory approval of blockbuster mAbs in therapeutic applications is expected to support the growth of the segment during the forecast period. For instance, significant revenue-generating drugs such as Avastin, Herceptin, Remicade, and Rituxan received FDA approval for various conditions, including cancer, rheumatoid arthritis, Crohn's disease, and ulcerative colitis, among others. Thus, monoclonal antibodies play a crucial role in modern healthcare, with promising growth scenarios fueled by ongoing technological advancements, therapeutic innovations, and the increasing risk of lifestyle-related chronic diseases, thereby positively influencing the overall growth of the custom antibody services market.

The recombinant antibody segment is expected to register the highest CAGR in the market during 2023–2031. Recombination antibodies are antibody fragments that are produced by synthetic genes. Recombination antibodies have found various applications in the field of medicine and research for the treatment of multiple sclerosis, dwarfism, anemia, rheumatoid arthritis, Crohn’s disease, and diabetes, among other diseases. Recombination antibody production is beneficial to human medicine by providing better penetration in tumor tissue compared to full-length IgG immunoglobulin.

Recombinant antibodies offer several benefits when compared to conventional antibodies. These benefits include the ability of recombinant antibodies to provide reproducible results and long-term supply and the ability to produce larger quantities as well as supply chain security and improved quality control in production. Recombinant antibodies offer flexibility, superior consistency across batches, and a continuous supply for antibody engineering. They are also highly specific and more sensitive than monoclonal antibodies. Recombinant antibodies are derived from DNA, and they do not need animal immunization or the use of animal serum in the production process. These benefits support the expansion of the recombinant antibodies segment.

The segment is also anticipated to grow during the forecast period as companies focus on strategic initiatives to enter the market. For instance, LSBio acquired Absolute Antibody Ltd. in December 2020 to broaden its product portfolio in recombinant antibodies. Absolute Antibody is an expert in recombinant antibody technology and provides custom services for the production of recombinant antibodies, antibody sequencing, and engineering.

The scope of the custom antibody services market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the custom antibody services market share in 2023. The presence of major companies, extensive government funding, and an increase in research activities in the region are a few of the key factors propelling the custom antibody services market growth in North America.

The growing incidences of infectious, chronic, and autoimmune diseases increase demand for custom antibody services in the US, favoring the custom antibody services market growth. Cancer is the second-highest cause of death in the country. According to a study published in the American Cancer Society, more than 1.9 million new cases of cancer were diagnosed in the US in 2022, while ~609,360 patients succumbed to the disease. The country is likely to record ~2.0 million new cancer diagnoses by the end of 2024. Custom antibodies are crucial in cancer treatment, aiding in detecting tumor-specific antigens and monitoring patient progress. The surge in research and development efforts, including a rise in the adoption of custom antibodies in oncology, immunology, stem cell, infectious disease, neurobiology, and cardiovascular disease research, further supports the custom antibody services market in the US. Agathos Biologics, a leading biotechnology and genetic medicine company, launched its recombinant adeno-associated virus (rAAV) production service in March 2024 by using its new AE1-BHK cell line. The company made the first sale of rAAV to a contract research and manufacturing organization, Genovac, which discovers, manufactures, and develops antibodies for therapeutic, diagnostic, and research applications.

The government invests significant amounts to support vaccine, therapeutic, and biomanufacturing projects in Canada. The government contributed US$ 23 million through the Strategic Innovation Fund to support Edesa Biotech's project with a total value of US$ 61 million. The company seeks to advance Phase III clinical trials for its monoclonal antibody therapy—EB05—to treat acute respiratory distress syndrome in COVID-19 patients. Edesa's therapy also has the potential to treat other pathogens known to cause pandemics, such as influenza. In May 2023, AbCellera announced a US$ 515 million (CA$ 701 million) co-investment with the governments of Canada and British Columbia to build new capabilities and infrastructure to develop state-of-the-art antibody-based medicines and strengthen the country's leadership in clinical research, manufacturing, and drug development. Moreover, technological advancements using recombinant antibodies are projected to bring new custom antibody services market trends in the coming years.

Thermo Fisher Scientific Inc.; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc.; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; and Creative Biolabs Inc. are among the leading companies profiled in the custom antibody services market report.

Based on product type, the custom antibody services market is categorized into monoclonal, polyclonal hybridoma, recombinant antibody, and others. By service type, the market is segmented into antibody discovery and development, antibody production services, and others. Based on application, the market is divided into immunohistochemistry, western blot & IP, ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. In terms of disease indication, the market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others. By source, the custom antibody services market is segmented into chicken, rabbits, rats, guinea pigs, mouse or humanized mice, and others. By end user, the market is segmented into the life science industry, pharmaceutical and biotech companies, academic and research institutes, and contract research organizations. Geographically, the market is categorized into North America (the US, Canada and Mexico), Europe (France, Germany, the UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).  

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com